The hypothesis underpinning our study was that higher FABP-4 may be positively associated with CRC risk, which could be biologically explained by facilitating tumor growth via increased fatty acid supply [13], or FABP-4-related enhancement of inflammation [14] and insulin resistance [15–18]. The gene discussed is INS; the disease is neoplasm.